A Guide to Online Pharmacy Merchant Services
Published - 11 April 2024
Revised - 23 July 2026


Libby James is the founder and Managing Director of Merchant Advice Service. Since 2016, she has worked directly with businesses and payment providers across merchant accounts, card processing, payment gateways and complex provider requirements.
Libby specialises in high-risk, declined and harder-to-place merchants, as well as businesses requiring specialist payment methods, integrations or international support. She writes and reviews Merchant Advice Service content, drawing on practical experience gained from real merchant enquiries and provider relationships.
Online pharmacies are one of the more complex businesses for payment providers to underwrite.
The challenge is not simply that medicines are sold online.
A payment provider may need to understand:
The rapid growth of private weight-management services and GLP-1 medicines has made this particularly important.
For established online pharmacies processing significant card volumes, the conversation can also move beyond simply getting a merchant account. Payment costs, authorisation rates, recurring-payment performance, settlement, reserves and gateway technology can all have a meaningful commercial impact.
This guide explains what payment providers assess, how weight-loss pharmacy payments differ from ordinary ecommerce and what established pharmacies should review as their business grows.
Yes.
UK online pharmacies can obtain merchant accounts and payment gateways, but the provider must knowingly support the pharmacy's business model and products.
A high-street pharmacy processing payments through a card terminal may be viewed differently from an online business taking prescription orders entirely through a website.
Online pharmacy underwriting may examine:
Pharmacies are commonly associated with MCC 5912 - Drug Stores and Pharmacies, although the acquiring provider is responsible for assigning the appropriate merchant category code according to the actual business activity. Current Visa and Mastercard merchant-category documentation includes pharmacies under MCC 5912.
For more complex pharmacy businesses, finding the right payment provider is therefore as much about regulatory fit and payment structure as transaction price.
Payment providers can be exposed to several different risks when processing online pharmacy transactions.
These include:
The underwriting question is not simply:
“Is this a registered pharmacy?”
It is closer to:
“Does the entire customer journey - from advertising and consultation through prescribing, payment, dispensing and delivery - fit within our acceptable-risk policy?”
That is a much more detailed assessment.
Weight management has become one of the most important areas of private online pharmacy.
Medicines such as semaglutide and tirzepatide have driven considerable growth in private weight-management services.
GLP-1 medicines are prescription-only medicines. The MHRA states that private patients must have an appropriate consultation with a healthcare professional before a prescription is issued and warns against buying these medicines from unregulated sellers or without a prior consultation.
From a payment-provider perspective, this means the transaction cannot necessarily be viewed like an ordinary online retail purchase.
An underwriter may want to understand:
The General Pharmaceutical Council's current guidance for pharmacist prescribers includes specific safeguards for weight-management medicines.
Before prescribing, the prescriber should independently verify the person's weight, height and/or BMI. This could be done through a video consultation, in person, using clinical records or through another healthcare provider. The guidance says verification by telephone would not be appropriate for the supply of weight-loss medication.
This is relevant to payment underwriting because the customer journey should not look like:
complete questionnaire → pay → automatically receive medicine
where there is no clear clinical decision between the request and the supply of treatment.
A payment provider is likely to want the actual medicines sold disclosed rather than an application simply stating:
“weight-loss treatments.”
The precise product matters.
The MHRA's current GLP-1 guidance lists medicines including semaglutide, tirzepatide and liraglutide, while also making clear that not every GLP-1 medicine is authorised for weight management.
For example, semaglutide is used in different medicines with different authorised indications.
An acquiring application should therefore clearly identify:
In June 2026, the MHRA also approved the UK's first GLP-1 receptor agonist tablet specifically for weight loss and weight management: a tablet formulation of semaglutide marketed as Wegovy.
This is a useful example of how quickly the product landscape is developing — and why a provider needs to understand what a pharmacy actually supplies rather than relying on broad terms such as “GLP-1 treatment”.
Legitimate pharmacy supply should not be confused with websites selling products that merely use the names of popular GLP-1 medicines.
The MHRA states that legitimate GLP-1 medicines are provided in authorised forms such as pre-filled injection pens or tablet formulations. It specifically warns that products supplied as powder in vials which need to be mixed before injection are not authorised GLP-1 medicines and pose significant health risks.
From a payment perspective, this creates a fundamentally different risk from a registered pharmacy dispensing authorised prescription medicines.
A provider may therefore examine:
This is one of the most important current compliance issues for online weight-management pharmacies.
Prescription-only medicines cannot be advertised to the general public.
Treatment providers can promote a service or consultation, but advertising must not become an invitation for members of the public to request a particular prescription-only medicine.
The MHRA continued taking action throughout 2026 against weight-management advertising that directly or indirectly promoted prescription-only medicines, including references to “weight-loss injections” and GLP-1 medication.
In June 2026, the MHRA, Advertising Standards Authority and GPhC also issued a joint warning about advertising newly licensed and as-yet unlicensed weight-management products. References such as “GLP-1 tablets”, “oral GLP-1s” or “new weight-loss tablets” can breach advertising rules when they promote prescription-only medicines to the public.
For payment underwriting, this means the provider may inspect much more than the checkout.
It may review:
This distinction matters.
A pharmacy could be:
but still create concerns for an acquiring bank because its website or advertising is too product-led.
That is why pharmacy underwriting needs to consider:
clinical governance + payment journey + commercial marketing
rather than registration alone.
Requirements vary, but merchants should be prepared for more detailed underwriting than an ordinary ecommerce retailer.
This may include:
A provider may ask for:
Where the website, prescribing service and pharmacy are operated by different companies, the relationship between them should be clearly explained.
The underwriter may want to understand:
Expect to disclose the complete product range.
This might include:
A merchant account approved for one business model should not be assumed to cover materially different products introduced later.
Online pharmacy businesses can involve several organisations.
For example:
Website operator → prescribing service → pharmacy → fulfilment provider → courier
Sometimes one company performs all of these functions.
Sometimes several independent companies are involved.
This can create confusion during underwriting.
The acquiring provider needs to understand:
The underlying business may be legitimate.
The problem is that the application leaves the underwriter trying to work out:
Who is actually selling what to whom?
Making the commercial and clinical structure clear from the beginning can avoid a significant amount of unnecessary back-and-forth.
This deserves careful consideration.
An online pharmacy should be able to explain what happens where:
What happens to the payment?
Is it:
The right model depends on the business.
The important point from an underwriting perspective is that the payment journey should make commercial sense alongside the clinical process.
Many private weight-management services operate on a repeat or monthly basis.
This creates an additional payment challenge.
Not every monthly pharmacy payment is simply a standard ecommerce subscription.
A recurring charge might include:
The provider needs to understand exactly what the customer is paying for.
A pharmacy using recurring card payments should understand:
Good recurring-payment design is not just a technical issue.
Poorly understood repeat charges can result in:
The merchant account and payment gateway perform different functions.
An online pharmacy may need:
Larger pharmacies may also need payment systems to connect with:
The cheapest gateway is not necessarily the right gateway for an online pharmacy.
Once an online pharmacy reaches meaningful scale, payments should be reviewed as part of the wider business rather than treated simply as a transaction fee.
A pharmacy may have started with:
website → payment gateway → one acquiring bank
That may have worked perfectly well while the business was smaller.
As turnover, patient numbers and repeat payments increase, different issues begin to matter:
At this stage, simply asking:
“Can you beat my processing rate?”
may miss the bigger opportunity.
For a high-turnover pharmacy, even a small difference in effective processing cost can translate into a material annual figure.
But cost is only one part of the equation.
A £1 million-per-month ecommerce business that improves legitimate payment acceptance could potentially benefit more from that improvement than from shaving a small amount from its transaction rate.
This means higher-volume pharmacies should understand:
The objective is:
lower cost + higher legitimate payment acceptance + better customer experience
rather than simply the lowest quoted percentage.
This is especially relevant to weight-management pharmacies.
At scale, a poorly configured recurring-payment process can result in substantial lost revenue.
The pharmacy should understand:
How is the first payment authenticated?
How are card details tokenised and stored securely?
Are later payments being correctly submitted as recurring or merchant-initiated transactions where applicable?
Does the provider support tools that can help update stored card credentials?
What happens when a legitimate recurring transaction declines?
Can an appropriate recoverable decline be retried?
Does the customer receive a secure link to update their card?
Are transactions which should not be retried being stopped?
Does stopping the treatment also stop the payment?
For high-volume recurring merchants, these details can have a material effect on revenue and chargebacks.
Higher-turnover ecommerce merchants should monitor how many genuine customer payments are being lost to declines.
A provider offering slightly cheaper processing may not represent a saving if fewer legitimate payments complete successfully.
Useful questions include:
For some businesses, improving these areas may be more valuable than renegotiating a few basis points.
Potentially.
Not every pharmacy needs multiple acquiring providers.
But a larger business may want to consider whether complete dependence on one provider creates operational risk.
A second properly underwritten acquiring route or payment-orchestration arrangement may potentially support:
Every provider should understand and approve the activity it processes.
Multiple merchant accounts should not be used to:
The purpose should be resilience and legitimate payment optimisation.
Some online pharmacies are required to maintain a rolling or fixed reserve.
A reserve that was reasonable when the company first launched may become financially significant as turnover grows.
For example, an established pharmacy may now have:
but still be operating under reserve terms originally agreed when the business had little track record.
It may be worth asking whether the current arrangement remains appropriate.
Possible areas for discussion include:
The provider does not have to reduce or remove a reserve.
But the effect on working capital should form part of any payment review.
Online pharmacies may have significant ongoing expenditure on:
Settlement therefore matters.
A merchant should compare:
A provider with a slightly higher transaction cost but materially better settlement may sometimes represent the better commercial arrangement.
Higher-turnover merchants should understand how their processing is priced.
A simple blended rate can be convenient.
For larger businesses, greater visibility may be useful.
IC++ pricing can separate:
This gives the merchant greater insight into where the cost of accepting different cards originates.
However, IC++ is not automatically cheaper.
The comparison should reflect the pharmacy's actual:
For a new pharmacy, the first question is often:
“Can I get an online pharmacy merchant account?”
For a pharmacy processing substantial monthly card volumes, the questions become different:
Are we paying the right amount?
How many genuine payments are being declined?
Is our recurring-payment setup working properly?
Are we holding unnecessary amounts of cash in reserve?
Could settlement improve?
Is our gateway limiting us?
Are we too dependent on one provider?
Can the current payment setup support the next stage of growth?
This is where MAS can look at the payment arrangement as a whole, rather than simply finding another acquiring bank.
If your pharmacy already processes significant card volumes, you do not need to wait until your existing provider causes a problem before reviewing the setup.
A useful starting point can include:
MAS can then consider:
processing cost + payment performance + recurring payments + settlement + reserves + technology + provider suitability
rather than simply comparing headline rates.
You do not need to cancel your existing provider to review your payment setup.
Potentially.
An established pharmacy should not assume that the merchant account it opened several years ago still represents the best arrangement.
A review may be worthwhile where:
But pharmacy merchants should be particularly careful when moving.
Do not cancel a functioning pharmacy merchant account on the strength of an attractive quote alone.
The replacement provider should have completed underwriting and knowingly approved:
before the old account is closed.
Online prescription-medicine businesses can face additional due diligence depending on the acquiring provider, card scheme, market and business model.
This can include further verification of the pharmacy or its authority to supply medicines online.
Do not assume every provider has identical requirements.
It is often worth establishing what a prospective payment provider actually requires before paying for third-party verification or certification.
Online pharmacies should also be aware that requirements are not identical throughout the UK.
Great Britain-based online medicine sellers have not been required to display the EU Distance Selling Logo since 1 January 2021.
Northern Ireland is different.
Anyone based in Northern Ireland selling medicines to the public online must still comply with the EU common Distance Selling Logo regime, register with the MHRA and display the logo on relevant pages offering medicines for sale.
Payment underwriters may therefore want to establish:
This should be treated separately.
A provider willing to accept a registered online pharmacy does not automatically accept research peptides, laboratory compounds or other products described as “research use only”.
Adding these products can materially change:
Where a pharmacy also sells research peptides, MAS would normally assess that part of the business separately rather than assume it falls within the pharmacy merchant account.
Read our separate guide to Peptide Merchant Accounts and Payment Processing.
There is rarely one universal reason.
Some providers simply exclude the sector.
The underwriter cannot establish who:
There may be insufficient explanation of how patients are assessed.
This remains a live enforcement issue. The MHRA's June 2026 decisions included businesses that changed advertising following concerns about direct or indirect promotion of prescription-only weight-loss medicines.
A general pharmacy may have moved heavily into weight management or another specialist treatment area after the original account was approved.
A provider may accept UK patients while excluding other countries.
High dispute levels can make an already specialist application much harder to place.
A new provider may still consider the business, but it will normally need to understand what happened to cause termination.
Common pharmacy disputes can include:
Recurring weight-management services need particular care.
Useful controls may include:
A high chargeback rate can affect:
Do not compare providers on transaction rate alone.
Does the provider knowingly support everything you sell?
Does it understand the relationship between the website, prescriber and pharmacy?
Can it work with your technology?
Are repeat-payment requirements properly supported?
Compare:
Understand:
When does the money actually reach you?
Check:
Which patient locations are supported?
Who helps when:
One of the quickest ways to waste time is submitting an application that simply says:
“Online pharmacy.”
That tells an underwriter very little.
MAS would rather understand:
before considering possible acquiring routes.
The aim is to approach providers whose appetite fits the real business, rather than generating unnecessary declines.
Merchant Advice Service helps businesses with more complex payment requirements understand their options and identify potential providers.
MAS can review the payment requirement before considering potential providers.
We can consider payment requirements for businesses providing private online weight-management services, including GLP-1 treatment models.
For established businesses processing significant volumes, the review can go beyond basic merchant-account approval.
This may include:
Requirements can include:
Where an application has already been declined, understanding the reason can help determine whether another provider is likely to be suitable.
Where processing has been closed, the reason should be established before replacement applications are made.
Recent processing history can be used to understand:
A lower rate is not necessarily the only opportunity.
A useful initial enquiry includes:
It is particularly useful to explain:
Where possible, also provide:
This helps MAS determine whether the main opportunity is:
cost reduction, better payment performance, improved technology or a combination of all three.
The first stage is understanding the business.
For an online pharmacy, this may involve:
For established high-turnover merchants, the review may go further into:
Where an appropriate route exists, MAS may introduce the merchant to a relevant payment provider or specialist partner.
The provider remains responsible for:
This article provides general payment information and is not pharmaceutical, clinical, regulatory or legal advice. Requirements depend on the particular pharmacy, medicines, business model and jurisdiction. Businesses should check current requirements with the appropriate regulators and professional advisers.
Written or reviewed by Libby James, founder of Merchant Advice Service and specialist in merchant payments and complex provider requirements.